These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 12497917)
1. [Surrogate end points in the assessment of benefits of antihypertensive treatment]. Salvetti A; Kozakova M; Buralli S Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):253-7. PubMed ID: 12497917 [No Abstract] [Full Text] [Related]
2. Correlations of left ventricular hypertrophy with cardiovascular mortality. Sharpe N Int J Clin Pract Suppl; 2000 May; (110):16-22. PubMed ID: 10912303 [No Abstract] [Full Text] [Related]
4. Clinical relevance of masked hypertension. Parati G Am J Hypertens; 2006 Sep; 19(9):887-8. PubMed ID: 16942928 [No Abstract] [Full Text] [Related]
5. Assessment of preclinical target organ damage in hypertesion: left ventricular hypertrophy. Rosei EA Blood Press; 2003; 12(3):183-4. PubMed ID: 12875482 [No Abstract] [Full Text] [Related]
6. Regression of left ventricular hypertrophy: lodestar to stroke prevention in the treatment of hypertension? Kizer JR; Devereux RB Am J Hypertens; 2006 May; 19(5):439-42. PubMed ID: 16647610 [No Abstract] [Full Text] [Related]
10. The year in hypertension. Williams B J Am Coll Cardiol; 2008 May; 51(18):1803-17. PubMed ID: 18452788 [No Abstract] [Full Text] [Related]
11. Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension. Hennersdorf MG; Schueller PO; Steiner S; Strauer BE Hypertens Res; 2007 Jun; 30(6):535-40. PubMed ID: 17664857 [TBL] [Abstract][Full Text] [Related]
12. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428 [TBL] [Abstract][Full Text] [Related]
13. Aortic elasticity, left ventricular geometry and diastolic dysfunction in hypertension. Karthikeyan VJ; Lip GY Int J Clin Pract; 2006 Nov; 60(11):1337-40. PubMed ID: 17073829 [No Abstract] [Full Text] [Related]
14. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416 [TBL] [Abstract][Full Text] [Related]
15. [Left ventricular hypertrophy in patients with arterial hypertension]. Diadyk AI; Bagriĭ AE; Lebed' IA; Iarovaia NF; Khomenko MV; Shpilevaia NI Lik Sprava; 1995; (7-8):68-73. PubMed ID: 8846379 [No Abstract] [Full Text] [Related]
16. Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression? Redon J Curr Opin Nephrol Hypertens; 2005 Sep; 14(5):448-52. PubMed ID: 16046903 [TBL] [Abstract][Full Text] [Related]
17. Further evidence for low-dose combinations in patients with left ventricular hypertrophy. Dahlöf B J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032 [TBL] [Abstract][Full Text] [Related]
19. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Gradman AH; Alfayoumi F Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048 [TBL] [Abstract][Full Text] [Related]
20. ["Soft" and "hard" end points in the example of hypertension]. Düsing R Dtsch Med Wochenschr; 2006 May; 131(19 Suppl 1):S21-6. PubMed ID: 16688661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]